Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 19/20 | 0.77 |
| ▸ | EGFR | P00533 | 1/20 | 0.54 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.54 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.53 |
| ▸ | AKT1 | P31749 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4745579 | 0.91 | PDPK1 (0.78) | PDPK1RPS6KB1AKT1 | |
| SCHEMBL4744842 | 0.87 | PDPK1 (1.00) | PDPK1RPS6KB1AKT1 | |
| SCHEMBL4744906 | 0.86 | PDPK1 (1.00) | PDPK1RPS6KB1AKT1 | |
| SCHEMBL4897866 | 0.85 | PDPK1 (1.00) | PDPK1RPS6KB1AKT1 | |
| SCHEMBL4744125 | 0.85 | PDPK1 (0.85) | PDPK1RPS6KB1AKT1 | |
| SCHEMBL4743567 | 0.85 | PDPK1 (0.79) | PDPK1RPS6KB1AKT1 | |
| SCHEMBL4888631 | 0.84 | PDPK1 (0.85) | PDPK1RPS6KB1AKT1 | |
| SCHEMBL4744229 | 0.84 | PDPK1 (0.81) | PDPK1RPS6KB1AKT1 | |
| SCHEMBL4743587 | 0.84 | PDPK1 (0.78) | PDPK1EGFRERBB2RPS6KB1AKT1 | |
| SCHEMBL4744360 | 0.83 | PDPK1 (0.85) | PDPK1RPS6KB1AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293712-A1 | Benzo[C][2,7]Naphtyridine Derivatives, Methods of Making Thereof and Methods of Use Thereof | WYETH (US) | 2008-11-27 | — | — | US | disclosed |
| WO-2008109613-A1 | BENZO[C][2,7]NAPHTHYRIDINE DERIVATIVES, AND THEIR USE AS KINASE INHIBITORS | WYETH (US) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293712-A1 | Benzo[C][2,7]Naphtyridine Derivatives, Methods of Making Thereof and Methods of Use Thereof | PDPK1, PDK2, PDK3 | PDPK1 1/4885EGFR 3929/4885ERBB2 1069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.